Abdalfattah Sharad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdalfattah Sharad has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hameed Salim Alkabi
Al-Rafidain University
1 shared publication - Hastyar Hamarashid Najmuldeen
Department of Medical Laboratory Analysis, College of Health Sciences, Cihan University Sulaimaniya, Sulaymaniyah City, Kurdistan, Iraq
1 shared publication - Imad Ghanem Qasim1 shared publication
- Karina Janisz1 shared publication
- Khalis Kadhim
Al-Mansour University College
1 shared publication - Kyrylo Voronezhskyi
Kyiv National University of Construction and Architecture
1 shared publication
Latest Publications
- 22 February 2026
- Published by Springer Nature
- p. 585-600
Workforce Retention in Volatile Labor Markets: Organizational Adaptation and Sectoral Resilience in the Post-Digital Economy
- 22 February 2026
- Published by Springer Nature
- p. 585-600
Workforce Retention in Volatile Labor Markets: Organizational Adaptation and Sectoral Resilience in the Post-Digital Economy
- 9 February 2026
- Published by Springer Nature
- p. 611-622
Artificial Intelligence in Criminal Justice: Examining Legal, Ethical, and Social Impacts
- 9 February 2026
- Published by Springer Nature
- p. 611-622
Artificial Intelligence in Criminal Justice: Examining Legal, Ethical, and Social Impacts
- Open Access
- 30 October 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 73-85
Glycoprotein G-Based Vaccines for Nipah Virus: Epidemiology, Molecular Insights, Benefits, and Limitations
Nipah virus (NiV) is a highly virulent zoonotic pathogen associated with significant mortality rates and limited treatment options, posing a significant public health threat. This review explores the epidemiology, molecular structure, and vaccine development efforts targeting glycoprotein G, a critical component of the virus's entry mechanism. Advances in structural biology and immunogenetics have highlighted the potential of glycoprotein G-based vaccines in preventing NiV infections. Despite promising preclinical results, challenges such as immune evasion, safety concerns, and limited clinical trials persist. Additionally, we examine the benefits of glycoprotein G-based vaccines in enhancing immune responses and preventing viral entry, as well as the limitations posed by genetic diversity and cross-reactivity. This review highlights the critical need for ongoing research to overcome existing challenges and guide future vaccine development efforts against NiV. It further underscores the necessity of innovative approaches in vaccine design to reduce the global burden of NiV infections. Glycoprotein G-based vaccines represent a promising avenue for combating NiV infections. Advances in structural biology, immune system targeting, and delivery system technology are paving the way for more effective vaccines. However, overcoming challenges such as cross-reactivity and safety concerns will require continued innovation and collaboration.
- 30 October 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 73-85
Open AccessGlycoprotein G-Based Vaccines for Nipah Virus: Epidemiology, Molecular Insights, Benefits, and Limitations
Nipah virus (NiV) is a highly virulent zoonotic pathogen associated with significant mortality rates and limited treatment options, posing a significant public health threat. This review explores the epidemiology, molecular structure, and vaccine development efforts targeting glycoprotein G, a critical component of the virus's entry mechanism. Advances in structural biology and immunogenetics have highlighted the potential of glycoprotein G-based vaccines in preventing NiV infections. Despite promising preclinical results, challenges such as immune evasion, safety concerns, and limited clinical trials persist. Additionally, we examine the benefits of glycoprotein G-based vaccines in enhancing immune responses and preventing viral entry, as well as the limitations posed by genetic diversity and cross-reactivity. This review highlights the critical need for ongoing research to overcome existing challenges and guide future vaccine development efforts against NiV. It further underscores the necessity of innovative approaches in vaccine design to reduce the global burden of NiV infections. Glycoprotein G-based vaccines represent a promising avenue for combating NiV infections. Advances in structural biology, immune system targeting, and delivery system technology are paving the way for more effective vaccines. However, overcoming challenges such as cross-reactivity and safety concerns will require continued innovation and collaboration.